TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group

Abstract Background Chemotherapy plus bevacizumab is a standard first-line treatment for unresectable metastatic colorectal cancer patients. Different chemotherapy backbones may be chosen, including one to three drugs, based on patients’ general conditions and comorbidities, treatments’ objectives,...

Full description

Bibliographic Details
Main Authors: Chiara Cremolini, Federica Marmorino, Fotios Loupakis, Gianluca Masi, Carlotta Antoniotti, Lisa Salvatore, Marta Schirripa, Luca Boni, Vittorina Zagonel, Sara Lonardi, Giuseppe Aprile, Emiliano Tamburini, Vincenzo Ricci, Monica Ronzoni, Filippo Pietrantonio, Chiara Valsuani, Gianluca Tomasello, Alessandro Passardi, Giacomo Allegrini, Samantha Di Donato, Daniele Santini, Alfredo Falcone, on behalf of all the investigators of the Gruppo Oncologico del Nord Ovest
Format: Article
Language:English
Published: BMC 2017-06-01
Series:BMC Cancer
Subjects:
Colorectal cancer
Bevacizumab
Strategy
Folfoxiri
Clinical trial
Online Access:http://link.springer.com/article/10.1186/s12885-017-3360-z

Internet

http://link.springer.com/article/10.1186/s12885-017-3360-z

Similar Items